Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07468526 Primaquine Phosphate Malaria, Vivax Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07468526 clinical trial report covering Primaquine Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467213 Zastaprazan citrate Gastrointestinal Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07467213 clinical trial report covering Zastaprazan citrate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07466953 Mesenchymal stem cell-derived suspended exosome(Yeditepe University Hospital) disorder of aging Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07466953 clinical trial report covering Mesenchymal stem cell-derived suspended exosome(Yeditepe University Hospital), Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07466316 Cyclophosphamide Rhabdomyosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07466316 clinical trial report covering Cyclophosphamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07469826 Tramadol Hydrochloride Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07469826 clinical trial report covering Tramadol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031250804 Diphtheria,Tetanus, Acellular Pertussis and Poliomyelitis Combined Vaccine, Inac Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
JPRN-jRCT2031250804 clinical trial report covering Diphtheria,Tetanus, Acellular Pertussis and Poliomyelitis Combined Vaccine, Inac, Phase 3, endpoints, sp
Latest Hotspot
8 min read
NCT07471282 Tenecteplase Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07471282 clinical trial report covering Tenecteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07469046 Omacetaxine Mepesuccinate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07469046 clinical trial report covering Omacetaxine Mepesuccinate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ISRCTN15146958 Nipocalimab-aahu Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ISRCTN15146958 clinical trial report covering Nipocalimab-aahu, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07469800 Mazdutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07469800 clinical trial report covering Mazdutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07470164 Onabotulinumtoxin A Esotropia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07470164 clinical trial report covering Onabotulinumtoxin A, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260985 Timolol Maleate Hemangioma, Capillary Infantile Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260985 clinical trial report covering Timolol Maleate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.